A Randomized, Phase IIb Clinical Trial to Evaluate the Safety and Antiviral Activity of the Combination of Pegylated Interferon Alfa Plus NM283 (Valopicitabine) in Treatment-Naive Patients With Chronic Hepatitis C
Phase of Trial: Phase II
Latest Information Update: 12 Dec 2014
At a glance
- Drugs Valopicitabine (Primary) ; Peginterferon alfa-2a
- Indications Hepatitis C
- Focus Therapeutic Use
- Sponsors Idenix Pharmaceuticals
- 06 Mar 2008 Status changed from in progress to discontinued as reported by Idenix.
- 30 May 2006 New trial record.